JAK1 and systemic sclerosis: Altered JAK1 signalling has been associated with T1DM previously, in studies that show JAK1 inhibition successfully ameliorated autoimmune diabetes in mice [20,21] and reduced insulin dependency in a patient with rheumatoid arthritis, systemic sclerosis, and T1DM [20].